Coriolus versicolor polysaccharide's protective effect on mice with acute lung injury and its influence on gut microbiota

doi:10.12092/j.issn.1009-2501.2026.05.004

Abstract

Abstract:

AIM: To investigate the protective effect of Coriolus versicolor polysaccharide on acute lung injury (ALI) mice and its influence on the intestinal microbiota. METHODS: Twenty-four mice were randomly divided into three groups: FC group (control group), FM group (LPS induced group), and FY group (Cordyceps polysaccharide prevention group). Mice in the FY group were given 200 mg/kg Coriolus versicolor polysaccharide by gavage daily, while mice in the FC group and FM group were given the same volume of normal saline by gavage daily for 15 days. 24 hours later, LPS (13 mg/kg) was intratracheally instilled into mice in the FM group and FY group to establish the ALI model. 12 hours after the model was established, samples were collected from the mice. The levels of IL-6, IL-10, IL-1β, TNF-α, T-AOC, SOD, GSH-Px, and MDA in the serum of the mice were detected; the pathological morphology changes of the lung tissue were observed via HE staining; and the changes in the intestinal microbiota of the mice were analyzed by sequencing technology. RESULTS: Compared with the FM group, the inflammatory cell infiltration in the lung tissue of mice in the FY group was reduced, and the thickening of the alveolar septum, pulmonary edema, and congestion of capillaries were improved; the levels of IL-6, IL-1β, and TNF-α in the blood were significantly decreased, and the antioxidant capacity was significantly increased. The analysis of the intestinal microbiota revealed that Coriolus versicolor polysaccharide regulated the relative abundance of the intestinal microbiota in mice, increasing the relative abundance of probiotics such as Lactobacillus, Actinomyces, and Bifidobacterium, and reducing the relative abundance of harmful bacteria such as Prevotella, maintaining intestinal homeostasis. CONCLUSION: Coriolus versicolor polysaccharide can exert anti-ALI effects by reducing inflammatory responses, enhancing antioxidant capacity, and regulating the intestinal microbiota of mice.

Key words: Coriolus versicolor polysaccharide, ALI, mice, intestinal microbiota

CLC Number:

R965.2

Rongxiang CAO, Yong LI. Coriolus versicolor polysaccharide's protective effect on mice with acute lung injury and its influence on gut microbiota[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 607-616.

Figures/Tables 14

Fig.1 Tracheal instillation method and experimental process

Table 1 Body weight of mice in each group ($\bar x \pm s$, n=8)

Item	FC	FM	FY
Initial body weight (g)	23.03±0.59	23.03±0.51	23.04±0.65
Final body weight (g)	28.49±2.01	28.47±1.93	29.49±1.97
Total weight gain (g)	5.46±1.53	5.44±1.81	6.44±1.75^b
Average daily weight gain (g)	0.30±0.08	0.30±0.10	0.35±0.10
Relative growth rate (%)	23.60±6.04	23.63±7.72	27.95±7.59^cf

Fig.2 Morphological changes in lung tissue of mice in each group (HE staining, 200×)

Fig.3 Lung indices of mice in each group ($\bar x \pm s $, n=8) bP<0.05, cP<0.01, compared with FM group.

Fig.4 Inflammatory cytokine levels in each group of mice ($ \overline{x} $±s, n=8) bP<0.05, cP<0.01, compared with FM group.

Fig.5 Antioxidant indicators of mice in each group ($ \overline{x} $±s, n=8) cP<0.01, compared with FM group.

Table 2 Statistical table of sequencing quantity of mouse samples in each group

Sample	Input	Filtered	Denoised	Merged	Non-chimeric	Non-singleton
FC1	95974	79998	79005	74111	66433	66415
FC2	99486	84913	84203	81513	77855	77842
FC3	96753	83239	82633	80781	77835	77832
FM1	99012	85626	84701	80255	69971	69954
FM2	88376	75943	75005	70268	53127	53072
FM3	100046	87187	86413	82583	73698	73678
FY1	110707	95362	94197	89312	80651	80634
FY2	114102	98349	97584	94328	87144	87118
FY3	102873	88575	88044	86201	80742	80737

Fig.6 Venn diagram Each ellipse represents a sample (group), and the overlapping area between ellipses indicates the common ASV/OTU between samples (groups). The number of each block indicates the number of ASV/OTUs contained in that block.

Fig.7 Alpha Diversity Analysis A: Grouping box plot of Alpha diversity index; B: Species accumulation curve plot; C: Abundance level curve plot.

Fig.8 Beta diversity analysis

Fig.9 Bar chart of species composition of mice in each group at the phylum (A) and genus (B) levels

Fig.10 Microbial communities with significant differences at the phylum level among different groups of mice ($ \overline{x} $±s, n=8) bP<0.05, cP<0.01, compared with FC group.

Fig.11 Microbial communities with significant differences at the genus level among different groups of mice ($ \overline{x} $±s, n=8) bP<0.05, cP<0.01, compared with FC group; eP<0.05, fP<0.01, compared with FM group.

Fig.12 LEfSe analysis A: display of inter group difference classification units based on classification level tree Figure; B: LDA effect value bar chart of marker species.

References 37

1	孙婧, 辛灵恩, 冯贤珍, 等. 白芍总苷对脂多糖诱导的小鼠急性肺损伤的保护作用及机制[J]. 首都医科大学学报, 2024, 45 (2): 302- 311.
2	Mokrá D. Acute lung injury-from pathophysiology to treatment [J]. Physiol Res, 2020, 69(Suppl 3): S353-S366.
3	Long ME, Mallampalli RK, Horowitz JC, et al. Pathogenesis of pneumonia and acute lung injury[J]. Clin Sci: Lond, 2022, 136 (10): 747- 769. doi: 10.1042/CS20210879
4	肖凌, 高春蕾, 郭伟, 等. 党参多糖通过调控MAPK/NF-κB信号通路对脂多糖诱导的急性肺损伤小鼠肺组织的保护作用[J]. 实用医学杂志, 2024, 40 (7): 948- 954.
5	Sandeep B, Xiao Z, Zhao F, et al. Role of platelets in acute lung injury after extracorporeal circulation in cardiac surgery patients: a systemic review[J]. Curr Probl Cardiol, 2022, 47 (11): 101088. doi: 10.1016/j.cpcardiol.2021.101088
6	刘澈, 马源, 董旭鹏, 等. 柚皮苷对脓毒症引起的急性肺损伤小鼠保护作用的研究[J]. 中国临床药理学杂志, 2024, 40 (5): 693- 697.
7	刘天涯. 地塞米松棕榈酸酯固体脂质纳米粒治疗急性肺损伤的研究 [D]. 成都: 成都大学, 2023.
8	柴新义, 朱文东, 陈美玲, 等. 野生云芝主要营养成分及其多糖抑菌效果[J]. 集宁师范学院学报, 2019, 41 (6): 10- 15.
9	葛唯佳. 杂色云芝多糖的提取、分离及药理活性研究 [D]. 吉林农业大学, 2019.
10	陈镕坤, 池延添, 易永旺, 等. 云芝多糖对肠道益生菌生长的影响[J]. 食品工业, 2024, 45 (1): 76- 79.
11	Mitoml T, Ogosh K. Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer[J]. Gan To Kagaku Ryoho, 1986, 13 (8): 252- 2537.
12	徐思源, 叶碧娴, 窦永会, 等. 云芝多糖调节炎症因子的表达并改善小鼠高脂血症[J]. 南开大学学报(自然科学版), 2016, 49 (3): 81- 87.
13	Jiang L, Zhang L, Kang K, et al. Resveratrol ameliorates LPS-induced acute lung injury via NLRP3inflammasome modulation[J]. Biomed Pharmacother, 2016, 84, 130- 138. doi: 10.1016/j.biopha.2016.09.020
14	张亚平, 张广平, 苏萍, 等. 不同途径吸入脂多糖致大鼠急性肺炎模型的优选[J]. 中国实验方剂学杂志, 2018, 24 (7): 82- 88.
15	杨健莉, 刘佳, 郑志红. 常用实验大小鼠采血方法及其对实验动物福利的影响[J]. 中国比较医学杂志, 2019, 29 (1): 90- 94.
16	张永玉, 龚娅, 刘荣碧, 等. 基于16S rRNA高通量测序技术初步探讨双歧杆菌乳杆菌三联活菌片对系统性红斑狼疮模型小鼠MRL/lpr肠道菌群的影响[J]. 风湿病与关节炎, 2024, 13 (1): 1- 7.
17	张茂福, 张志明, 宋忠阳, 等. 中药调控氧化应激防治急性肺损伤的研究进展[J]. 中草药, 2024, 55 (9): 3190- 3201.
18	Kapur R, Rebetz J, Velden SVD, et al. Pancreatic involvement in murine antibody-mediated transfusion-related acute lung injury ?[J]. Transfusion, 2021, 61 (3): 987- 989.
19	俞莉, 叶苗云, 陈少丹, 等. 基于肠道菌群和代谢组学研究桦褐孔菌多糖对急性肺损伤小鼠的保护作用[J]. 中国实验方剂学杂志, 2024, 30 (13): 86- 94.
20	Yuan Q, Basit A, Liang W, et al. Pazopanib ameliorates acute lung injuries via inhibition of MAP3K2 and MAP3K3[J]. Sci Transl Med, 2021, 13 (591): 132- 138. doi: 10.1126/scitranslmed.abc2499
21	Zhong WJ, Liu T, Yang HH, et al. TREM-1 governs NLRP3 inflammasome activation of macrophages by firing up glycolysis in acute lung injury[J]. Int J Biol Sci, 2023, 19 (1): 242- 257.
22	夏彦民, 王文辰, 张鸿, 等. 人羊膜上皮细胞气管内滴注对脂多糖诱导小鼠急性肺损伤的保护作用[J]. 细胞与分子免疫学杂志, 2017, 33 (1): 7- 11.
23	杨开燕, 魏惠平, 王记, 等. 基于肠心轴学说探讨肠道菌群在心血管疾病中的作用[J]. 中国现代应用药学, 2023, 40 (24): 3467- 3472.
24	瞿光友, 彭友飞, 陈怡名, 等. 基于16S rDNA测序技术分析益气活血方对脑缺血损伤大鼠肠道菌群多样性的影响[J]. 现代中药研究与实践, 2024, 38 (4): 24- 30.
25	Jones SE, Lennon JT. Dormancy contributes to the maintenance of microbial diversity[J]. Proc Natl Acad Sci USA, 2010, 107 (13): 5881- 5886.
26	邵兰, 徐进步. 肠道菌群通过戊酸调节脂多糖诱导的急性肺损伤[J]. 中国微生态学杂志, 2024, 36 (10): 1163- 1169.
27	马鸣, 汪坤, 杨艳华, 等. 基于p38 MAPK/MLCK信号通路探讨通腑泻肺灌肠液对急性肺损伤大鼠肠道屏障及肠道菌群的影响[J]. 中国中药杂志, 2024, 49 (21): 5919- 5931.
28	Li Y, Liu XY, Ma MM, et al. Changes in intestinal microflora in rats with acute respiratory distress syndrome[J]. World J Gastroenterol, 2014, 20 (19): 5849- 5858.
29	邓贵凤. 芍药甘草汤通过重塑肠道菌群调节TLR4/NF-KB信号通路改善多囊卵巢综合征的作用机制研究 [D]. 太原: 山西医科大学, 2021.
30	钟海. 三叶苷对LPS诱导急性肺损伤小鼠的保护作用及机理研究 [D]. 广州: 南方医科大学, 2021.
31	Li W, Ding ZH, Chen Y, et al. Integrated pharmacology reveals the molecular mechanism of Gegen qinlian decoction against lipopolysaccharide-induced acute lung injury[J]. Front Pharmacol, 2022, 13, 854544.
32	Ma PJ, Wang MM, Wang Y. Gut microbiota: a new insight into lung diseases[J]. Biomed Pharmacother, 2022, 155, 113810.
33	张甘纯, 刘文, 宋信莉, 等. 芍药甘草汤对急性肺损伤大鼠肠道菌群的影响[J]. 中国药房, 2023, 34 (17): 2063- 2068.
34	Boweeman KL, Rehman SF, Vaughan A, et al. Disease-associated gut microbiome and metabolome changes in patients with chronic obstructive pulmonary disease[J]. Nat Commun, 2020, 11 (1): 5886.
35	Chang ZP, Deng GF, Shao YY, et al. Shaoyao-Gancao Decoction ameliorates the inflammation statein polycystic ovary syndrome rats via remodeling gut microbiota and suppressing the TLR4/NF-kB pathway[J]. Front Pharmacol, 2021, 12, 670054.
36	王平, 赵澄, 卢芳国, 等. 麻杏石甘汤对流感病毒感染小鼠肠道菌群及趋化因子CCL5、CXCL10的影响[J]. 中草药, 2021, 52 (1): 160- 175.
37	Sanadat J, Hosomi K, Shoj H, et al. Gut microbiota modification suppresses the development ofpulmonary arterial hypertension in an SU5416/hypoxia rat model [J]. Pulm Circ, 2020, 10(3): 2045894020929147.

[1]	Xiaoyan GAO, Juan GUO, Sheng HUANG, Qiaoyun WANG, Yujia HUANG, Jinyuan LI, Xiaoqiang LIU. Mechanism of Qinggan Ershiqiwei Wan on non-alcoholic steatohepatitis based on network pharmacology and in vivo experiments [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 596-606.
[2]	Mei CHENG, Zhaohui FANG, Jindong ZHAO, Fengxia SHENG, Mengnan MA. Liraglutide combined with metformin on glycolipid metabolism level and intima-media thickness in overweight/obese patients with type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 623-630.
[3]	Qun LI, Xinyue ZHANG, Shuo QI, Jin TAN. Research progress on the mechanism of TGF-β1/Smads signaling pathway in oral submucous fibrosis and regulation of traditional Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 666-674.
[4]	Haodong YANG, Long LI, Jingxuan LUO, Jinglei LI. Research progress of Hippo pathway effector YAP/TAZ in idiopathic pulmonary fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(5): 709-715.
[5]	Wenli DONG, Ruohao ZHANG, Beining GUO, Jing ZHANG, Yuhong XU, Baowei PENG, Xiaofen LIU. Progress and application of phenylhydrazine derivatization combined with LC-MS/MS for quantitative analysis of carbonyl metabolites in biological samples [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(4): 517-526.
[6]	Yajie BAI, Liuqing YANG, Qin FAN, Xuwei LIU, Yuchen HE, Jiamao CHENG, Haiyan CHEN. The anti-hepatic fibrosis mechanism of Dendrobium officinale poly saccharides in vitro through epithelial-mesenchymal transition and Notch signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(3): 337-343.
[7]	Writing team for "Chinese expert consensus on blood drug monitoring for arsenic trioxide". Chinese expert consensus on blood drug monitoring for arsenic trioxide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 185-195.
[8]	Pengfei WANG, Yuwei WANG, Fangmei JIN, Ping CHEN, Weiqing LI, Xuemei TIAN, Aihua WANG, Haidong WANG. The mechanism of action of Yiqi Huoluo formula in regulating the PI3K/Akt/mTOR pathway to suppress synovial inflammation in collagen-induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(2): 213-222.
[9]	Tao WANG, Xiaowen CHENG, Zhirui ZHANG, Hao JIAO. Shikonin restrains TGF-β1/Smad signaling pathway to improve renal fibrosis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 48-54.
[10]	Zhiwang WANG, Yue ZHANG, Ping QUAN, Yue ZHAO, Bei TIAN, Haijing DUAN, Ruiqiong WANG. Progress in the study of interleukin-17A-mediated signaling network regulating airway remodeling in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 88-95.
[11]	Jianqiang DU, Qi ZHANG, Enpeng GU, Chen XU, Yuan GUO, Menglong ZHANG, Jinke GUO, Si WU, Haibo XIE. Advances in the modulation of Nrf2 signaling by natural compounds for the treatment of intervertebral disc degeneration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(1): 116-124.
[12]	ZOU Hong, QI Shuo, LI Dandan, DENG Fangping, CHEN Shuangshuang, FU Shuxin, TANG Zheng, TANGQun. Hepatotoxicity of Brucea javanica bitter alcohol in nude mice based on liver drug metabolizing enzyme CYP450 expression [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1049-1057.
[13]	LI Xingui¹, XU Daliang², YU Biao¹, GU Yun¹, DENG Yan¹, ZHANG Shihai³. Effect of high-dose methotrexate on alkaline phosphatase in children with acute lymphoblastic leukemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1099-1104.
[14]	LIU Xun, ZHOU Tingting, ZHU Zibing, TAN Jin, LI Qun. Arecoline promotes oral submucous fibrosis by upregulating PI3K/Akt/mTOR signaling pathway in vivo and in vitro [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(7): 865-875.
[15]	DING Qin, YANG Ruwei, ZHANG Shengnan, YANG Guoping, PEI Qi. Time-to-event analysis in evaluating the efficacy of drugs against multidrug-resistant gram-negative bacterial infections [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(7): 998-1008.